Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial
about
Bisphosphonates in multiple myeloma: a network meta-analysisBisphosphonates and other bone agents for breast cancerBisphosphonates in multiple myelomaBisphosphonates for breast cancerZoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administrationOff-trial evaluation of bisphosphonates in patients with metastatic breast cancerAdjuvant bisphosphonates in patients with breast cancer: does the potency matter?Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationBiology of bone metastases.Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaChemotherapy- and irradiation-induced bone loss in adults with solid tumorsBone-targeted therapy in metastatic breast cancer - all well-established knowledge?Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compoundAnti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to boneDelaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesionsUse of intravenous bisphosphonates in older women with breast cancerComparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis.Direct antitumour activity of zoledronic acid: preclinical and clinical data.Bone-targeting agents in prostate cancer.The best of both worlds - managing the cancer, saving the bone.Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisReverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.Evidence for using bisphosphonate to treat Legg-Calvé-Perthes diseaseCirculating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot studyZoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials.Synthesis, characterization and in vitro evaluation of new composite bisphosphonate delivery systems.In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.Treatment and prevention of bone complications from prostate cancer.Management of skeletal metastases: An orthopaedic surgeon's guideBisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.NCCN Task Force Report: Bone Health in Cancer Care.Bone cement augmentation procedures for spinal pathologic fractures by multiple myelomaManagement of complications of androgen deprivation therapy in the older man.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Contemporary therapeutic approaches targeting bone complications in prostate cancer
P2860
Q24197839-C5434883-5D75-4C67-B03C-05653B39C8CCQ24203656-1954F7A5-7D57-4112-B331-6A5EFCD28DC3Q24236776-718DB6B6-E38A-4A24-BF25-88F16EEBF3BAQ24246519-5A02A950-A493-46FB-91DD-E10A278FB732Q24650864-4B0EC7F4-EA55-4889-9620-86EE8D2C1432Q24811840-2B1CA3EE-A9D8-41B2-999A-957AA551252AQ26781435-F4B307E1-F17E-4B6D-BA1A-789B385E2289Q26824762-9734AEE7-EFC2-445D-9481-4F451EA247C2Q27002668-BFB4E007-E3EA-4BFC-9D44-4B4447BCBB4BQ27693653-C163E3CF-BAE1-44CC-A146-565964517D52Q28076646-543B8837-6AFB-4E34-B1DD-BC61A0EC396EQ28081996-10F6BCA0-869D-4153-8BE2-006C7B207910Q28084019-B20931EE-6065-464D-A2F8-AEBDABA76FB3Q28087676-7AC5116B-AF71-43AC-9BE0-7F6705536D3AQ28543939-DDEA688C-6466-4092-90C1-8446636875A7Q28742851-DFF7D8F9-6FBB-4BC9-BA62-3E43CF90A0F8Q30684593-8C44DDE5-5844-44D4-BCE6-823558A03F8EQ31048683-9C63FC8C-3515-4DA1-94D6-849869EE1EB2Q33666930-4AECD4BD-3D7F-48B4-A718-2AE0ECF22470Q33727640-A2ADC36F-BC83-4CC4-A3A3-CCAF1C180C48Q33844438-2F6A9FC1-7DDC-4264-88A5-943486B9230CQ33850938-2978AC0C-1883-4523-B806-7FCD914AE091Q33864723-0C318C59-D223-49E3-A78D-2E4BD649A530Q33920055-8FFDA815-0F06-4B16-91B2-14B52EED4EC7Q34042003-26DD31F6-E768-4BB8-8F31-F871898A8911Q34127953-EA4B5689-572B-4B9A-8F16-D80566726336Q34249155-633D8EAB-D4A0-441B-BF3A-333D52743DFEQ34294905-8C5BAAF9-2B70-4318-B963-10466C3940C3Q34320376-910AA26A-1463-47AE-BC76-1316B7CC650EQ34359069-BE514B65-D8E1-4555-BF75-B1D6692F088DQ34427554-B9E3E025-E8F7-4ECB-969A-AB1A528DDF33Q34441944-78C72E0B-0B98-4B1D-81C1-43FBA40122B2Q34458440-9401B172-2B16-46EA-8A7B-1B8D9CF807A9Q34458449-54890FDE-22DA-4C20-A55A-78D444028A40Q34583705-944C2066-B6E9-47D0-8099-9F095E551621Q34617936-82C973A0-D706-4FD6-99EF-549A24840466Q34779509-BBDFF037-2796-4013-9B72-7146680E9BFFQ34782101-AA957E0A-4CD4-457E-BE27-56B82FD71026Q34939979-22C9AB01-4ACE-48B0-B31B-D4EDAC87927AQ34960778-E397B94C-C4D3-48A3-A50B-7B2D4AFB9F41
P2860
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Long-term efficacy and safety ...... multicenter, comparative trial
@en
Long-term efficacy and safety ...... multicenter, comparative trial
@nl
type
label
Long-term efficacy and safety ...... multicenter, comparative trial
@en
Long-term efficacy and safety ...... multicenter, comparative trial
@nl
prefLabel
Long-term efficacy and safety ...... multicenter, comparative trial
@en
Long-term efficacy and safety ...... multicenter, comparative trial
@nl
P2093
P356
P1433
P1476
Long-term efficacy and safety ...... multicenter, comparative trial
@en
P2093
Andrew Belch
Bee-Lian Chen
David Gordon
Dirk J Reitsma
John J Seaman
John Mackey
Justus Apffelstaedt
Lee S Rosen
Mary Kaminski
Mohamad A Hussein
P304
P356
10.1002/CNCR.11701
P407
P577
2003-10-01T00:00:00Z